Shares of Neurocrine Biosciences Inc. spiked then relaxed Tuesday after an investment firm speculated that Pfizer Inc. could justify an acquisition of the company to position itself in the growing insomnia treatment market.
Shares of Neurocrine Biosciences Inc. spiked then relaxed Tuesday after an investment firm speculated that Pfizer Inc. could justify an acquisition of the company to position itself in the growing insomnia treatment market.
